ASH 2019 | Novel therapeutic for AML: CYC065 combinations

Mhairi Copland

Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, outlines a study that aimed to assess the effects of CYC065, a novel CDK2/9 inhibitor, on the growth and survival of acute myeloid leukemia (AML) cells. The study also evaluated the synergistic effect of CYC065 in combination with other targeted or chemotherapy agents. Results show that CYC065 pulse treatment effectively induced apoptosis in AML cell lines in vitro and a synergistic effect of CYC065 in combination with venetoclax, cytarabine or azacitidine was observed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter